Program
comekibart
Also written as “MG-K10”, “MG-K10 Injection” and “MG-K10 Injection (Humanized Monoclonal Antibody)”.
Its studies are mostly in Nasal Polyps · Chronic Urticaria · Dermatitis, Atopic, led by Shanghai Mabgeek Biotech..
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Mabgeek Biotech. | 33 open or running | phase 3since Apr 13, 2026 | Apr 13, 2026 | Jan 5, 2027phase 3 · NCT07540442 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 13, 2026First study: phase 3 study in Dermatitis, AtopicFirst studyNCT07540442 · 180 planned · China
- Sep 14, 2026Phase 2 study in Chronic UrticariaNCT07838727 · 60 planned
- Oct 14, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07903194 · 210 planned
Ahead
- Jan 5, 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07540442
- May 7, 2027Primary completion: phase 2 study in Chronic UrticariaNCT07838727
- Dec 21, 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07903194
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07903194Chronic Rhinosinusitis With Nasal Polyps | 3 | Not yet recruiting | Dec 21, 2027 | 210 |
| NCT07838727Chronic Urticaria | 2 | Not yet recruiting | May 7, 2027 | 60 |
| NCT07540442Dermatitis, Atopic · China | 3 | Not yet recruiting | Jan 5, 2027 | 180 |
How it is read
Names in the registry
- “MG-K10”, 1 entry
- “MG-K10 Injection”, 1 entry
- “MG-K10 Injection (Humanized Monoclonal Antibody)”, 1 entry
Conditions, from the studies’ own filings
- Nasal Polyps, 1 study
- Chronic Urticaria, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.